Perth mum's bikini start-up lands spot at NY Swim Week
The annual event offers sought-after exposure for both global and emerging labels, with EllaMarie believed to be the only Aussie label on display.
Based out of Savvy Brands' retail store in East Fremantle but building a strong online presence, the 39-year-old describes her pieces as 'very sexy, very sleek' and adjustable to suit many body types. Ella Marie Swimwear has received a call-up to New York Swim Week. Credit: Unknown / EllaMarie Swimwear
She said she's often struggled to find quality swimwear to fit her curvy body, and is hoping her range will fill a 'gap in the market'.
'I've always been about feeling confident, feeling powerful, feeling good within your own skin,' she told PerthNow.
With a focus on sustainability, EllaMarie's pieces are crafted from Italian producer Carvico's innovative fabrics — comprising 78 per cent recycled fibres, and featuring chlorine resistance, an SPF 50+ sun rating, and a high degree of durability.
Allocated 10 pieces to showcase, Ms Conte has no shortage of suitors lining up to try them on.
'I've had probably 50 American models contact me, asking if they can model for me for the show,' she revealed.
Her 'OG collection' will continue to be sold through the Aussie summer, with tops typically priced at $65 and bottoms from $65. Lauree Conte launched the swimwear brand in January. Credit: Unknown / EllaMarie Swimwear
The entrepreneur, who has worked in mining for 20 years, was inspired by her seven-year-old daughter Ella Marie to launch the label but admits juggling all of her priorities has proven difficult.
She hopes the brand will become successful enough to afford her more time at home.
'Being able to come home every single day, drop my daughter at school and pick her up is essentially the end goal,' she said.
'Currently working in corporate mining, I'm never there.'
With the mother's side hustle New York-bound, Ms Conte is buoyed by the recognition she has already received and the prospect of exposure on a grand scale.
'I'm just very excited to go and represent Western Australia in the big smoke., and we'll do our best,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News AU
12 minutes ago
- Sky News AU
Australian dollar sees sharp move following shock RBA cash rate decision
InTouch Capital Markets' Sean Callow claims he was 'surprised' by the RBA's cash rate decision. This comes amid the Reserve Bank of Australia deciding to keep the cash rate on hold at 3.85 per cent despite wide speculation of a rate cut. 'I was surprised, and the Aussie dollar reaction tells you that FX traders were as well,' Mr Callow told Sky News Business Reporter Edward Boyd.
The Age
3 hours ago
- The Age
Chalmers rules out using PBS as bargaining chip in face of Trump's pharma tariffs
Australian officials are rushing to learn the details of Donald Trump's threatened 200 per cent tariff on pharmaceutical imports, which could hit more than $2 billion of Australian goods each year in a major escalation of the president's global trade war. But Treasurer Jim Chalmers ruled out changes to Australia's prized Pharmaceutical Benefits Scheme, which subsidises medicines and secures discounts through bulk buying from manufacturers, infuriating the American industry that views it as anti-competitive. Trump said he plans to implement a 50 per cent duty on US copper imports, while also indicating he could offer pharmaceutical manufacturers at least a year before applying a crippling 200 per cent tariff on their foreign-made products. 'They're going to be tariffed at a very, very high rate, like 200 per cent,' Trump told reporters at a cabinet meeting on Tuesday. 'We'll give them a certain period of time to get their act together.' Pharmaceutical products are the third-biggest category in Australia's exports to the US, after beef and gold. The category is worth about $US1.3 billion a year and includes plasma exports from biotech giant CSL, a company that also has large US operations. Loading Chalmers said on Wednesday that Australian copper exports to the US were less than 1 per cent of total trade, but pharmaceuticals were worth much more. 'Our pharmaceuticals industry is much more exposed to the US market, and that's why we're seeking, urgently seeking, some more detail on what's been announced,' he told ABC Radio National Breakfast. 'I want to make it really clear once again, as we have on a number of occasions before, our pharmaceutical benefit scheme is not something that willing to we're willing to trade away or do deals on.'
Sydney Morning Herald
3 hours ago
- Sydney Morning Herald
Chalmers rules out using PBS as bargaining chip in face of Trump's pharma tariffs
Australian officials are rushing to learn the details of Donald Trump's threatened 200 per cent tariff on pharmaceutical imports, which could hit more than $2 billion of Australian goods each year in a major escalation of the president's global trade war. But Treasurer Jim Chalmers ruled out changes to Australia's prized Pharmaceutical Benefits Scheme, which subsidises medicines and secures discounts through bulk buying from manufacturers, infuriating the American industry that views it as anti-competitive. Trump said he plans to implement a 50 per cent duty on US copper imports, while also indicating he could offer pharmaceutical manufacturers at least a year before applying a crippling 200 per cent tariff on their foreign-made products. 'They're going to be tariffed at a very, very high rate, like 200 per cent,' Trump told reporters at a cabinet meeting on Tuesday. 'We'll give them a certain period of time to get their act together.' Pharmaceutical products are the third-biggest category in Australia's exports to the US, after beef and gold. The category is worth about $US1.3 billion a year and includes plasma exports from biotech giant CSL, a company that also has large US operations. Loading Chalmers said on Wednesday that Australian copper exports to the US were less than 1 per cent of total trade, but pharmaceuticals were worth much more. 'Our pharmaceuticals industry is much more exposed to the US market, and that's why we're seeking, urgently seeking, some more detail on what's been announced,' he told ABC Radio National Breakfast. 'I want to make it really clear once again, as we have on a number of occasions before, our pharmaceutical benefit scheme is not something that willing to we're willing to trade away or do deals on.'
